Table III.
Frequency of NOTCH1, SF3B1, MDM2 and MYD88 mutations in patients with CLL and controls.
| Mutation | Patients with CLL, n (%) | Controls, n (%) | χ2 (P-value) | OR (95%CI), P-value |
|---|---|---|---|---|
| NOTCH1 | ||||
| Wild-type | 90 (90.0) | 100 (100.0) | ||
| Mutant | 10 (10.0) | 0 (0.0) | 11.04 (0.001) | |
| SF3B1 | ||||
| Wild-type | 88 (88.0) | 103 (98.1) | 8.2 (0.004) | 7.02 (1.53–32.23), 0.012 |
| Mutant | 12 (12.0) | 2 (1.9) | ||
| MDM2 mutation | ||||
| Ins/Ins | 52 (52.5) | 51 (51.5) | ||
| Ins/Del | 39 (39.4) | 34 (34.3) | 0.15 (0.70) | |
| Del/Del | 8 (8.1) | 14 (14.1) | 1.45 (0.22) | |
| MYD88 | ||||
| TT (wild-type) | 100 (100.0) | 105 (100.0) | ||
| TC | 0 (0.0) | 0 (0.0) | ||
| CC | 0 (0.0) | 0 (0.0) |
CLL, chronic lymphocytic leukemia; NOTCH1, Notch homolog 1, translocation-associated (Drosophila); SF3B1, splicing factor 3B subunit 1; MDM2, murine double minute 2; MYD88, myeloid differentiation primary response 88; OR, odds ratio; CI, confidence interval; Ins, insertion; Del, deletion.